Adicet Bio, Inc. Increase (Decrease) in Accrued Liabilities
Adicet Bio, Inc. (ACET) reported Increase (Decrease) in Accrued Liabilities of -$4.39 million for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-07-30.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2020-07-30
- Adicet Bio, Inc. increase (decrease) in accrued liabilities for the quarter ending 2020-06-30 was -$258.00K, a 217.81% decline year-over-year.
- Adicet Bio, Inc. increase (decrease) in accrued liabilities for the quarter ending 2020-03-31 was -$4.13M.
- Adicet Bio, Inc. increase (decrease) in accrued liabilities for the quarter ending 2019-12-31 was $3.26M.
- Adicet Bio, Inc. increase (decrease) in accrued liabilities for the quarter ending 2019-09-30 was $756.00K.
- Adicet Bio, Inc. increase (decrease) in accrued liabilities for fiscal 2019 was $2.76M.
- Adicet Bio, Inc. increase (decrease) in accrued liabilities for fiscal 2018 was -$1.02M, a 127.26% decline from fiscal 2017.
- Adicet Bio, Inc. increase (decrease) in accrued liabilities for fiscal 2017 was $3.75M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2020-06-30 | -$258.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | -$4.39M 10-Q · filed 2020-07-30 | -$1.12M derived: sum of 3 quarters · filed 2020-07-30 | -$367.00K derived: sum of 4 quarters · filed 2020-07-30 |
| 2020-03-31 | -$4.13M 10-Q · filed 2020-05-07 | -$865.00K derived: sum of 2 quarters · filed 2020-05-07 | -$109.00K derived: sum of 3 quarters · filed 2020-05-07 | $110.00K derived: sum of 4 quarters · filed 2020-07-30 |
| 2019-12-31 | $3.26M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $4.02M derived: sum of 2 quarters · filed 2020-03-12 | $4.24M derived: sum of 3 quarters · filed 2020-07-30 | $2.76M 10-K · filed 2020-03-12 |
| 2019-09-30 | $756.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $975.00K derived: sum of 2 quarters · filed 2020-07-30 | -$507.00K 10-Q · filed 2019-11-05 | -$1.14M derived: sum of 4 quarters · filed 2020-07-30 |
| 2019-06-30 | $219.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | -$1.26M 10-Q · filed 2020-07-30 | -$1.90M derived: sum of 3 quarters · filed 2020-07-30 | -$5.10M derived: sum of 4 quarters · filed 2020-07-30 |
| 2019-03-31 | -$1.48M 10-Q · filed 2020-05-07 | -$2.12M derived: sum of 2 quarters · filed 2020-05-07 | -$5.32M derived: sum of 3 quarters · filed 2020-05-07 | -$3.61M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | -$636.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$3.84M derived: sum of 2 quarters · filed 2020-03-12 | -$2.13M derived: sum of 3 quarters · filed 2020-03-12 | -$1.02M 10-K · filed 2020-03-12 |
| 2018-09-30 | -$3.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$1.49M derived: sum of 2 quarters · filed 2019-11-05 | -$386.00K 10-Q · filed 2019-11-05 | $2.34M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $1.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $2.82M 10-Q · filed 2019-08-14 | $5.55M derived: sum of 3 quarters · filed 2020-03-12 | $6.38M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $1.10M 10-Q · filed 2019-05-15 | $3.83M derived: sum of 2 quarters · filed 2020-03-12 | $4.66M derived: sum of 3 quarters · filed 2020-03-12 | |
| 2017-12-31 | $2.73M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $3.56M derived: sum of 2 quarters · filed 2020-03-12 | $3.75M 10-K · filed 2020-03-12 | |
| 2017-09-30 | $829.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $1.02M 10-Q · filed 2018-11-13 | ||
| 2017-06-30 | $193.00K 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | $1.00K 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |